Verastem, Inc.

NasdaqCM:VSTM

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

Location

United States

Market Cap

USD 250.57 M

Share Price

USD 4.56

Avg Daily Volume

1,580,079

Change (1 day)

-1.30%

Change (1 year)

47.10%

Change (YTD)

-11.80%

Verastem, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2025

Verastem, Inc. Free Cash Flow Per Share is NA for the Trailing 12 Months (TTM) ending March 31, 2025. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.

Verastem, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -3.85, a -2.17% change year over year.
Verastem, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -3.94, a 10.54% change year over year.
Verastem, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -3.56, a -11,301.18% change year over year.
Verastem, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 0.03, a -100.16% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Free Cash Flow Per Share	Dividend Per Share	Debt to Equity Ratio	Quick Ratio

NasdaqCM: VSTM

Verastem, Inc.

CEO	Mr. Daniel W. Paterson
IPO Date	Jan. 27, 2012
Location	United States
Headquarters	117 Kendrick Street
Employees	78
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology

Description

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.